Skip to main content
. 2019 Nov 21;2019:3435901. doi: 10.1155/2019/3435901

Figure 1.

Figure 1

Effects of BMS-833923 treatment on the osteoblast differentiation of human bone marrow skeletal (mesenchymal) stem cells (hMSCs). (a) Representative alkaline phosphatase (ALP) staining of BMS-833923-treated hMSCs (3.0 μM) on day 10 postosteoblastic differentiation compared to DMSO-treated control cells. Magnification: 10x. (b) Quantification of ALP activity in BMS-833923-treated hMSCs (3.0 μM) on day 10 postosteoblastic differentiation compared to DMSO-treated control cells. (c) Assay for cell viability using alamarBlue assay BMS-833923-treated hMSCs (3.0 μM) on day 10 postosteoblastic differentiation compared to DMSO-treated control cells. Data are presented as mean ± SEM (n = 16). DMSO: dimethyl sulfoxide.